These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19882396)

  • 1. HIV provider endorsement of primary care buprenorphine treatment: a vignette study.
    Kunins HV; Sohler NL; Roose RJ; Cunningham CO
    Fam Med; 2009; 41(10):722-8. PubMed ID: 19882396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians.
    Cunningham CO; Kunins HV; Roose RJ; Elam RT; Sohler NL
    J Gen Intern Med; 2007 Sep; 22(9):1325-9. PubMed ID: 17619934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nurse practitioner and physician assistant interest in prescribing buprenorphine.
    Roose RJ; Kunins HV; Sohler NL; Elam RT; Cunningham CO
    J Subst Abuse Treat; 2008 Jun; 34(4):456-9. PubMed ID: 17664052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
    Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.
    Alford DP; LaBelle CT; Kretsch N; Bergeron A; Winter M; Botticelli M; Samet JH
    Arch Intern Med; 2011 Mar; 171(5):425-31. PubMed ID: 21403039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mixed methods study of HIV-related services in buprenorphine treatment.
    Knudsen HK; Cook J; Lofwall MR; Walsh SL; Studts JL; Havens JR
    Subst Abuse Treat Prev Policy; 2017 Aug; 12(1):37. PubMed ID: 28814313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models for integrating buprenorphine therapy into the primary HIV care setting.
    Basu S; Smith-Rohrberg D; Bruce RD; Altice FL
    Clin Infect Dis; 2006 Mar; 42(5):716-21. PubMed ID: 16447120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients.
    Abraham R; Wilkinson E; Jabbarpour Y; Petterson S; Bazemore A
    J Am Board Fam Med; 2020; 33(1):9-16. PubMed ID: 31907241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
    Friedland G; Vlahov D
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
    [No Abstract]   [Full Text] [Related]  

  • 13. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital.
    Cunningham CO; Sohler NL; McCoy K; Kunins HV
    Fam Med; 2006 May; 38(5):336-40. PubMed ID: 16673195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.
    Walley AY; Alperen JK; Cheng DM; Botticelli M; Castro-Donlan C; Samet JH; Alford DP
    J Gen Intern Med; 2008 Sep; 23(9):1393-8. PubMed ID: 18592319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
    Chaudhry AA; Botsko M; Weiss L; Egan JE; Mitty J; Estrada B; Lucas GM; Woodson T; Flanigan TP; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S14-21. PubMed ID: 21317589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practice Predictors of Buprenorphine Prescribing by Family Physicians.
    Peterson LE; Morgan ZJ; Borders TF
    J Am Board Fam Med; 2020; 33(1):118-123. PubMed ID: 31907252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The medical management of opioid dependence in HIV primary care settings.
    Lum PJ; Tulsky JP
    Curr HIV/AIDS Rep; 2006 Nov; 3(4):195-204. PubMed ID: 17089480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to primary care physicians prescribing buprenorphine.
    Hutchinson E; Catlin M; Andrilla CH; Baldwin LM; Rosenblatt RA
    Ann Fam Med; 2014; 12(2):128-33. PubMed ID: 24615308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
    Hawkins EJ; Malte CA; Hagedorn HJ; Gordon AJ; Williams EC; Trim RS; Blanchard BE; Lott A; Danner AN; Saxon AJ
    J Addict Med; 2024 May-Jun 01; 18(3):240-247. PubMed ID: 38329814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients.
    Kresina TF; Eldred L; Bruce RD; Francis H
    AIDS; 2005 Oct; 19 Suppl 3():S221-6. PubMed ID: 16251822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.